Arrhythmias & electrophysiologyMeta-analysis
Identification of biomarkers for predicting new-onset atrial fibrillation: a systematic review and meta-analysis
- Systematic review and meta-analysis of cohort studies
- PRISMA 2020
- Quality assessed with the Newcastle-Ottawa scale
Authors' conclusion
Well-known biomarkers, such as NT-proBNP, and others not yet incorporated into clinical practice, such as Lp(a) and sVCAM-1, could play a role in the diagnosis and preventive management of AF.
Study context
- Population
- Patients without prior or postoperative atrial fibrillation (AF); studies of specific populations excluded
- Participants
- 472,581 patients · 10 cohort studies
- Outcome
- New-onset AF, by biomarker
Pooled result
As reported in the abstract
- Biomarkers associated with increased AF risk, most notably NT-proBNP and sVCAM-1
- 18
- Biomarkers associated with lower AF incidence
- 9
- ADAMTS13 and AF incidence, HR
- 0.78 (95% CI 0.70-0.88)
- NT-proBNP (meta-analysis) and AF incidence, HR (95% CI 1.19-1.59); I2 = 80%, p<0.01
- 1.37
- Lp(a): significant increase in AF incidence per 20 mg/dL increment
- 3%
Original publication
Identification of biomarkers for predicting new-onset atrial fibrillation: a systematic review and meta-analysis. Eur J Prev Cardiol. Published 29 January 2026. doi:10.1093/eurjpc/zwag061
Summarised from the published abstract; every number is checked against it